BD-pTau 217 is a refined biomarker which enhances Alzheimer’s specificity while retaining the strengths of plasma pTau 217.
BOSTON, April 16, 2026--(BUSINESS WIRE)--Delve Bio, a UCSF spin-out and pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, announced data underscoring the clinical ...
CHICAGO, April 25, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development and commercialization of molecular diagnostics targeting central nervous system ...
(MENAFN- Investor Brand Network) Primary and metastatic central nervous system (CNS) tumors can have extraordinary biological and anatomical complexity, and these tumors can be hard to identify using ...
-Delve Bio to Present Two Oral Presentations at American Academy of Neurology 2026 Annual Meeting- Delve Bio, a UCSF spin-out and pioneer in metagenomic next-generation sequencing (mNGS) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results